(Q60976563)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

S. Vincent Rajkumar

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

8

M Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

2

M Lacy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

5

F Buadi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

9

D Dingli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

6

K Detweiler-Short

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

S Sinha

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

J Mikhael

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

S Hayman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

S K Kumar

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

11 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

839-841

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.279

14 February 2020

exact match

0 references

cites work

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

https://api.crossref.org/works/10.1038%2FLEU.2011.279

1 reference

7 January 2021

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.279

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.279

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21986842%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference